Application of a yeast assay to detect functional p53 mutations in archival prostate cancer tissue

Cancer Biotherapy and Radiopharmaceuticals

Volumn 17, Issue 6, 2002, Pages 657-664

  Shi, Xu Bao ^a   Di Mauro, Stephen M ^a   Highshaw, Ralph ^a   Deitch, Arline D ^a   Evans, Christopher P ^a   Gumerlock, Paul H ^a   DeVere White, Ralph W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Archival tissue; p53 mutation; Prostate cancer; Yeast assay

Indexed keywords

FORMALDEHYDE; PARAFFIN; PROTEIN P53;

ALLELE; ARTICLE; ASSAY; DNA SEQUENCE; EVALUATION; EXON; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MALE; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; YEAST; YEAST ASSAY;

EID: 0036921603     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497802320970262     Document Type: Article

References (31)

1. Hussain SP, Harris CC. Molecular epidemiology of human cancer: Contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 1998;58:4023-4037.
2. Fronza G, Inga A, Monti P, Scott G, Campomenosi P, Menichini P, Ottaggio L, Viaggi S, Bums PA, Gold B, Abbondandolo A. The yeast p53 functional assay: A new tool for molecular epidemiology. Hopes and facts. Mutat Res 2000;462:293-301.
3. O'Connell MJ, Walworth NC, Carr AM. The G2-phase DNA-damage checkpoint. Trends Cell Biol 2000;10:296-303.
4. Li GM. The role of mismatch repair in DNA damage-induced apoptosis. Oncol Res 1999;11:393-400.
5. Shen Y, White E. p53-dependent apoptosis pathways. Adv Cancer Res 2001;82:55-84.
6. deVere White RW, Deitch AD, Gumerlock PH, Shi XB. Use of a yeast assay to detect functional alterations in p53 in prostate cancer: Review and future directions. Prostate 1999;41:134-142.
7. Di Como CJ, Prives C. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene 1998;16:2527-2539.
8. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994;54:3131-3135.
9. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-1669.
10. Chi SG, deVere White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH. p53 in prostate cancer: Frequent expressed transition mutations. J Natl Cancer Inst 1994;86:926-933.
11. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, Srivastava S. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 1995;154:414-421.
12. Stricker HJ, Jay JK, Linden MD, Tamboli P, Amin MB. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Urol 1996;47:366-369.
13. Meyers FJ, Gumerlock PH, Chi SG, Borchers H, Deitch AD, deVere White RW. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 1998;83:2534-2539.
14. Brewster SF, Oxley JD, Trivella M, Abbott CD, Gillatt DA. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol 1999;161:1238-1243.
15. Stackhouse GB, Sesterhenn IA, Bauer JJ, Mostofi FK, Connelly RR, Srivastava SK, Moul JW. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 1999;162:2040-2045.
16. Downing SR, Jackson P, Russell PJ. Mutations within the tumor suppressor gene p53 are not confined to a late event in prostate cancer progression. A review of the evidence. Urol Oncol 2001;6:103-110.
17. Moul JW. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol 1999;35:399-407.
18. Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, Forman JD, Mesic J, Fu KK, Abrams RA, Pajak TF, Shipley WU, Cox JD. p53 status and prognosis of locally advanced prostatic adeno-carcinoma: A study based on RTOG 8610. J Natl Cancer Inst 1997;89:158-165.
19. Gumerlock PH, Chi SG, Shi XB, Voeller HJ, Jacobson JW, Gelmann EP, deVere White RW. p53 abnormalities in primary prostate cancer: Single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. J Natl Cancer Inst 1997;89:66-71.
20. Hayashi K, Yandell DW. How sensitive is PCR-SSCP? Human Mutation 1993;2:338-346.
21. Melhem MF, Law JC, El-Ashmawy L, Johnson JT, Landreneau RJ, Srivastava S, Whiteside TL. Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol 1995;146:1170-1177.
22. Waridel F, Estreicher A, Bron L, Flaman JM, Fontolliet C, Monnier P, Frebourg T, Iggo R. Field cancerization and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene 1997;14:163-169.
23. Shi XB, Bodner SM, deVere White RW, Gumerlock PH. Identification of p53 mutations in archival prostate tumors: Sensitivity of an optimized single-strand conformational polymorphism (SSCP) assay. Diag Mol Pathol 1996;5:271-278.
24. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher JM, Bron L, Benhattar J, Tada M, Van Meir EG, Estreicher A, Iggo RD. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995;92:3963-3967.
25. van Oijen MG, Slootweg PJ. Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 2000;6:2138-2145.
26. Shi XB, Nesslinger NJ, Deitch AD, Gumerlock PH, deVere White RW. Complex functions of mutant p53 alleles from human prostate cancer. Prostate 2002;51:59-72.
27. Tada M, Iggo RD, Waridel F, Nozaki M, Matsumoto R, Sawamura Y, Shinohe Y, Ikeda J, Abe H. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: Comparison with conventional structural analyses. Mot Carcinog 1997;18:171-176.
28. Kashiwazaki H, Tonoki H, Tada M, Chiba I, Shindoh M, Totsuka Y, Iggo R, Moriuchi T. High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogene 1997;15:2667-2674.
29. Martin A, Flaman JM, Frebourg T, Davi F, El Mansouri S, Amouroux J, Raphael M. Functional analysis of the p53 protein in AIDS-related non-Hodgkin's lymphomas and polymorphic lymphoproliferations. Br J Haematol 1998;101:311-317.
30. Frebourg T, Flaman JM, Estreicher A, Iggo R. Functional Assay of the p53 Tumor Suppressor Gene. Mutation Detection: A Practical Approach. Oxford; LRL Press, 1998;211-221.
31. Williams C, Ponten F, Moberg C, Soderkvist P, Uhlen M, Ponten J, Sitbon G, Lundeberg J. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 1999;155:1467-1471.